摘要
目的探讨负荷剂量阿托伐他汀对非ST段抬高急性冠状动脉综合征（NSTEACS）患者PCI围手术期的影响。方法将160例NSTEACS患者随机分为负荷剂量治疗80例为观察组和标准治疗80例为对照组。观察组PCI术前3~5d给予负荷剂量阿托伐他汀40mg/d,对照组PCI术前3~5d给予常规剂量阿托伐他汀10mg/d,两组其余药物治疗均相同,PCI治疗相同。主要检测指标为术前、术后6h、12h、24h肌酸激酶同工酶（CK-MB）、心肌肌钙蛋白（cTnI）水平变化,随访术后30d内主要不良心脏事件（MACE）发生率。结果与PCI术前比较,观察组术后8h、24hCK-MB、cTnI升高水平均明显低于对照组,两组比较差异具有统计学意义（P〈0.05）;观察组术后30d内MACE的发生率明显低于对照组,两组比较差异具有统计学意义（P〈0.05）。结论 NSTEACS患者PCI术前应用负荷剂量阿托伐他汀能减少PCI术对患者造成的心肌损伤,降低PCI术后不良心脏事件的发生率,安全有效,临床可广泛应用。
Objective To investigate the loading dose of atorvastatin on the PCI perioperative period in pa- tients with non-ST segment elevation acute coronary syndrome （NSTEACS）. Methods One hundred and sixty pa- tients with NSTEACS were randomly divided into the observation group and the control group, each with 80 cases. The observation group was given a loading dose of atorvastatin （40 mg/d） 3-5 days PCI preoperatively, while the con- trol group was given conventional dose of atorvastatin （10 mg/d） 3-5 days PCI preoperatively. The remaining medica- tions applied and the PCI treatment performed were the same in the two groups. The levels of creatine kinase isoen- zyme （CK-MB） and cardiac troponin I （cTnI） were detected before operation, and 8 h, 12 h, 24 h after operation. The incidence of major adverse cardiac events （MACE） was investigated 30 days after operation. Results The increase in the levels of CK-MB, cTnI 8 h, 24 h after operation was significantly lower than that in the control group （P〈0.05）, compared with the levels before operation. The incidence of MACE of the observation group 30 days after operation was significantly lower than that of the control group （P〈0.05）. Conclusion For patients with NSTEACS, the appli- cation of loading dose of atorvastatin before PCI can lighten the myocardial damage causes by PCI and reduce the inci- dence of MACE after PCI, which is safe, effective, and worthy to be widely applied in clinic.
出处
《海南医学》
CAS
2012年第19期22-24,共3页
Hainan Medical Journal
